GNI Group Ltd.
2160 | T
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- Japan
- Address:
- 中央区日本橋本町二丁目２番２号
- Website:
- https://www.gnipharma.com/
- Sector:
- Health Care
- Industry:
- Pharmaceuticals
Description
GNI Group Ltd. is a Japanese biopharmaceutical company focused on developing innovative therapies to address unmet medical needs. The company is involved in the research and development of novel treatments, particularly in the fields of oncology and rare diseases, leveraging advanced biotechnology. GNI Group engages in strategic partnerships and collaborations to enhance its product pipeline and accelerate drug development. With a commitment to improving patient outcomes, the company aims to deliver cutting-edge solutions that can transform healthcare. Recent announcements include participation in conferences and the launch of new therapies, reflecting GNI's active role in the global biopharmaceutical landscape.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-04-23 09:00 |
Inside Information Statement
臨時報告書
|
Japanese | 32.7 KB | |
| 2025-03-31 09:00 |
Regulatory News Service
確認書
|
Japanese | 8.2 KB | |
| 2025-03-31 09:00 |
Internal Control over Financial Reporting
内部統制報告書－第24期(2024/01/01－2024/12/31)
|
Japanese | 22.2 KB | |
| 2025-03-31 09:00 |
Annual Report
有価証券報告書－第24期(2024/01/01－2024/12/31)
|
Japanese | 1.2 MB | |
| 2025-03-28 03:30 |
Inside Information Statement
臨時報告書
|
Japanese | 21.6 KB | |
| 2024-08-14 10:08 |
Inside Information Statement
臨時報告書
|
Japanese | 19.0 KB | |
| 2024-08-14 09:26 |
Interim Report
半期報告書－第24期(2024/01/01－2024/12/31)
|
Japanese | 301.9 KB | |
| 2024-08-14 09:26 |
Regulatory News Service
確認書
|
Japanese | 10.0 KB | |
| 2024-07-02 08:00 |
Regulatory News Service
訂正報告書（大量保有報告書・変更報告書）
|
Japanese | 51.9 KB | |
| 2024-06-28 09:00 |
Major Shareholding Notification
大量保有報告書
|
Japanese | 52.6 KB | |
| 2024-05-30 09:30 |
Inside Information Statement
臨時報告書
|
Japanese | 32.3 KB | |
| 2024-05-15 09:02 |
Quarterly Report
四半期報告書－第24期第1四半期(2024/01/01－2024/03/31)
|
Japanese | 255.3 KB | |
| 2024-05-15 09:02 |
Regulatory News Service
確認書
|
Japanese | 10.0 KB | |
| 2024-03-29 02:00 |
Inside Information Statement
臨時報告書
|
Japanese | 21.7 KB | |
| 2024-03-28 08:32 |
Inside Information Statement
臨時報告書
|
Japanese | 19.1 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
Idorsia Ltd | Switzerland | IDIA | |
|
ILIKA PLC | United Kingdom | IGE | |
|
Immuno-Biological Laboratories Co., Ltd. | Japan | 4570 | |
|
Indivior PLC | United Kingdom | INDV | |
|
Infant Bacterial Therapeutics | Sweden | IBT | |
|
Initiator Pharma A/S | Denmark | INIT | |
|
Intercure Ltd. | Israel | INCR | |
|
Intervacc AB | Sweden | IVACC | |
|
Ipsen | France | IPN | |
| JCR Pharmaceuticals Co.,Ltd. | Japan | 4552 |